{
    "organizations": [],
    "uuid": "fc39e1e30d66658c8a1fcbbd4ec6427c85235bfe",
    "author": "",
    "url": "https://www.reuters.com/article/brief-miragen-therapeutics-reports-qtrly/brief-miragen-therapeutics-reports-qtrly-loss-per-share-0-29-idUSASC09S9J",
    "ord_in_thread": 0,
    "title": "BRIEF-Miragen Therapeutics Reports Qtrly ‍loss Per Share $0.29​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " Miragen Therapeutics Reports Qtrly ‍loss Per Share $0.29​   Miragen Therapeutics Inc: * MIRAGEN THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE * MIRAGEN THERAPEUTICS INC QTRLY ‍LOSS PER SHARE $0.29​ * MIRAGEN THERAPEUTICS INC - ‍INTENDS TO INITIATE A PHASE 2 CLINICAL TRIAL FOR COBOMARSEN IN PATIENTS WITH CTCL IN SECOND HALF OF 2018​  ",
    "published": "2018-03-14T22:24:00.000+02:00",
    "crawled": "2018-03-14T22:39:04.037+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "miragen",
        "therapeutic",
        "report",
        "qtrly",
        "per",
        "share",
        "miragen",
        "therapeutic",
        "inc",
        "miragen",
        "therapeutic",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "provides",
        "corporate",
        "update",
        "miragen",
        "therapeutic",
        "inc",
        "qtrly",
        "per",
        "share",
        "miragen",
        "therapeutic",
        "inc",
        "initiate",
        "phase",
        "clinical",
        "trial",
        "cobomarsen",
        "patient",
        "ctcl",
        "second",
        "half"
    ]
}